表紙
市場調查報告書

非何傑金氏淋巴瘤:開發中產品分析

Non-Hodgkin Lymphoma - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 192737
出版日期 內容資訊 英文 3473 Pages
訂單完成後即時交付
價格
非何傑金氏淋巴瘤:開發中產品分析 Non-Hodgkin Lymphoma - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 3473 Pages
簡介

非何傑金氏淋巴瘤(NHL,或僅稱「淋巴瘤」),是從人體免疫系統淋巴球發病的癌症之一。人體各處均有可能出現,癌細胞擴展速度也完全因人而異。主要的症狀有盜汗、間歇性發熱·發冷、發癢、頭部·腋下·鼠蹊部等淋巴節肥大化、體重減少、咳嗽·呼吸急促(胸腺和胸部淋巴節受侵襲)、氣管和其他呼吸道的壓迫感、腹痛·膨脹感、食慾不振、便秘、噁心·嘔吐·頭痛、欠缺集中力、性格變化、癲癇(腦部受侵襲)等。主要的治療方法有外科手術和放射治療、化療等。

本報告提供全球各國治療非何傑金氏淋巴瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

非何傑金氏淋巴瘤概要

治療藥的開發

非何傑金氏淋巴瘤:治療藥的評估

非何傑金氏淋巴瘤開發治療藥的企業

藥物簡介

非何傑金氏淋巴瘤治療藥:開發暫停的產品

非何傑金氏淋巴瘤治療藥:開發中止的產品

非何傑金氏淋巴瘤相關產品的開發里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12253IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 2, 36, 203, 194, 4, 24, 172, 19 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages comprises 25, 29, 2, 1, 39, 4 and 1 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Non-Hodgkin Lymphoma - Overview
  • Non-Hodgkin Lymphoma - Therapeutics Development
  • Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • Non-Hodgkin Lymphoma - Drug Profiles
  • Non-Hodgkin Lymphoma - Dormant Projects
  • Non-Hodgkin Lymphoma - Discontinued Products
  • Non-Hodgkin Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2020
  • Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H1 2020

List of Figures

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020